|Awarded On||November 02, 2011|
|Title||Oncometabolites in Renal Cancer|
|Award Mechanism||High Impact/High Risk|
|Institution/Organization||The University of Texas Health Science Center at San Antonio|
|Principal Investigator/Program Director||Karen Block|
|Cancer Sites||Kidney and Renal Pelvis|
Renal Cancer is among the 10 most common malignancies in both men and women. Despite the recent approval of new therapies to target this malignancy, the reality is that most patients with advanced disease will not survive (median survival 13 months). Hence, the elucidation of novel molecular mechanisms is needed to develop more effective therapies for this deadly disease. Increasing evidence supports the paradigm that cancer development is tightly linked to alterations in metabolism. Metabolism refers to the complex set of chemical reactions that are required by an organism to conduct the basic processes required for survival. As a result, our laboratory has performed a comprehensive me...